Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526965 | 0.79 | LOX (0.31) | — | |
| SCHEMBL19677742 | 0.78 | HDAC1 (0.31) | GRM5 | |
| SCHEMBL2767368 | 0.77 | GRM5 (0.50) | GRM5 | |
| SCHEMBL31242414 | 0.77 | GRM5 (0.50) | GRM5 | |
| SCHEMBL19781323 | 0.76 | KDM1A (0.34) | — | |
| SCHEMBL20929147 | 0.76 | LOX (0.32) | — | |
| SCHEMBL19781318 | 0.76 | — | — | |
| SCHEMBL28449756 | 0.75 | EGLN2 (0.38) | EGLN2GRM5 | |
| SCHEMBL6649045 | 0.74 | TRPV4 (0.61) | TRPV4EGLN2 | |
| SCHEMBL1478000 | 0.73 | LOX (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889610-B2 | Alpha-D-galactoside inhibitors of galectins | GALECTO BIOTECH AB (DK) | 2021-01-12 | — | — | US | disclosed |
| US-20190315793-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2019-10-17 | — | — | US | disclosed |
| CN-109563119-A | α-D- galactoside the inhibitor of galactose agglutinin | 格莱克特生物技术公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2018011094-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315793-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS1, LGALS3, LGALS2 | TRPV4 4169/4885EGLN2 2299/4885GRM5 1710/4885 |
| US-10889610-B2 | Alpha-D-galactoside inhibitors of galectins | LGALS1, LGALS3, LGALS2 | TRPV4 4169/4885EGLN2 2299/4885GRM5 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.